These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25889426)

  • 21. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
    García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
    J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.
    Wijbrandts CA; van Leuven SI; Boom HD; Gerlag DM; Stroes EG; Kastelein JJ; Tak PP
    Ann Rheum Dis; 2009 Aug; 68(8):1316-21. PubMed ID: 18723565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Association between systemic inflammation and autoimmunity parameters and plasma lipid in patients with rheumatoid arthritis].
    Xue C; Liu WL; Sun YH; Ding RJ; Hu DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):941-5. PubMed ID: 22321280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease.
    Chen DY; Hsieh TY; Chen YM; Hsieh CW; Lan JL; Lin FJ
    Gerontology; 2009; 55(3):250-8. PubMed ID: 18849599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
    Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
    Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
    Cauza E; Cauza K; Hanusch-Enserer U; Etemad M; Dunky A; Kostner K
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):1004-7. PubMed ID: 12635469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis.
    Novikova DS; Popkova TV; Lukina GV; Luchikhina EL; Karateev DE; Volkov AV; Novikov AA; Aleksandrova EN; Nasonov EL
    J Korean Med Sci; 2016 Feb; 31(2):202-7. PubMed ID: 26839473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies against oxidized LDL and atherosclerosis in rheumatoid arthritis patients treated with biological agents: a prospective controlled study.
    Papamichail GV; Georgiadis AN; Tellis CC; Rapti I; Markatseli TE; Xydis VG; Tselepis AD; Drosos AA; Voulgari PV
    Clin Rheumatol; 2024 Jan; 43(1):481-488. PubMed ID: 37642764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    Naerr GW; Rein P; Saely CH; Drexel H
    Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
    Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
    PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment.
    Mathieu S; Pereira B; Dubost JJ; Lusson JR; Soubrier M
    Rheumatology (Oxford); 2012 Jun; 51(6):1107-11. PubMed ID: 22328565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.
    van Sijl AM; Peters MJ; Knol DL; de Vet RH; Sattar N; Dijkmans BA; Smulders YM; Nurmohamed MT
    Semin Arthritis Rheum; 2011 Dec; 41(3):393-400. PubMed ID: 21665247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
    Hitchon CA; Alex P; Erdile LB; Frank MB; Dozmorov I; Tang Y; Wong K; Centola M; El-Gabalawy HS
    J Rheumatol; 2004 Dec; 31(12):2336-46. PubMed ID: 15570632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.
    Choy E; Sattar N
    Ann Rheum Dis; 2009 Apr; 68(4):460-9. PubMed ID: 19286905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.